In his career Joe M. had done some work (not known in what capacity or what was accomplished) for three or four of the big name pharma companies of today. He should have some lasting inside lines of communications with some top dogs in those firm who he might persuade to sell the GNBT COVID proprietary vaccine rights. Those companies are awash with cash and if there is any substance to what is being developed, they might jump at such at premium and be willing to pay a premium particularly if the current development team is structured into a deal . Its time to bail out the shareholders who have been thumped in the rear end but what appears to be a management debacle of extraordinary proportions.
Generex Biotechnology Corp. (GNBT) Stock Research Links